AU2010294292B2 - Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer - Google Patents

Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer Download PDF

Info

Publication number
AU2010294292B2
AU2010294292B2 AU2010294292A AU2010294292A AU2010294292B2 AU 2010294292 B2 AU2010294292 B2 AU 2010294292B2 AU 2010294292 A AU2010294292 A AU 2010294292A AU 2010294292 A AU2010294292 A AU 2010294292A AU 2010294292 B2 AU2010294292 B2 AU 2010294292B2
Authority
AU
Australia
Prior art keywords
alkyl
benzenesulfonamide
methyl
butan
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010294292A
Other languages
English (en)
Other versions
AU2010294292A1 (en
Inventor
Karen Miller-Moslin
Bakary-Barry Toure
Michael Scott Visser
Naeem Yusuff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2010294292A1 publication Critical patent/AU2010294292A1/en
Application granted granted Critical
Publication of AU2010294292B2 publication Critical patent/AU2010294292B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2010294292A 2009-09-10 2010-09-08 Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer Ceased AU2010294292B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24125109P 2009-09-10 2009-09-10
US61/241,251 2009-09-10
PCT/EP2010/063169 WO2011029842A1 (en) 2009-09-10 2010-09-08 Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2010294292A1 AU2010294292A1 (en) 2012-03-01
AU2010294292B2 true AU2010294292B2 (en) 2013-07-18

Family

ID=43016684

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010294292A Ceased AU2010294292B2 (en) 2009-09-10 2010-09-08 Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer

Country Status (12)

Country Link
US (1) US8809352B2 (https=)
EP (1) EP2475661B1 (https=)
JP (1) JP2013504536A (https=)
KR (1) KR20120078715A (https=)
CN (1) CN102498111A (https=)
AU (1) AU2010294292B2 (https=)
BR (1) BR112012005343A2 (https=)
CA (1) CA2772989A1 (https=)
EA (1) EA020586B1 (https=)
ES (1) ES2443845T3 (https=)
MX (1) MX2012003007A (https=)
WO (1) WO2011029842A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG192126A1 (en) * 2011-01-25 2013-09-30 Univ Michigan Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
EP2794588A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
JP2015503518A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Bcl2と結合相手の相互作用を阻害するための化合物
LT6064B (lt) 2012-10-15 2014-08-25 Vilniaus Universitetas Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai
CN105636945B (zh) 2013-10-14 2017-11-17 卫材R&D管理有限公司 选择性取代的喹啉化合物
JP6223563B2 (ja) 2013-10-14 2017-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的に置換されたキノリン化合物
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
US10975051B2 (en) * 2015-08-12 2021-04-13 Memorial Sloan Kettering Cancer Center Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
EP3936153B1 (en) 2016-01-11 2024-08-21 Celator Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and rad3-related protein (atr)
WO2017123616A1 (en) * 2016-01-11 2017-07-20 Merrimack Pharmaceuticals, Inc. Inhibiting b-cell lymphoma 2 (bcl-2) and related proteins
SI3788042T1 (sl) 2018-04-29 2025-06-30 Beigene Switzerland Gmbh Zaviralci BCL-2
AU2020256166A1 (en) 2019-04-02 2021-10-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
WO2021083135A1 (en) 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
JP7839962B2 (ja) 2020-04-15 2026-04-03 ビーワン メディシンズ ワン ゲーエムベーハー Bcl-2阻害剤
EP4538273A1 (en) * 2022-06-10 2025-04-16 Hitgen Inc. Compound and use thereof in preparation of bcl-xl inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008061208A2 (en) * 2006-11-15 2008-05-22 Genentech, Inc. Arylsulfonamide compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1487811B1 (en) * 2002-03-21 2007-09-05 Abbott Laboratories N-sulfonylurea apoptosis promoters
US20040157836A1 (en) * 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
EP1778206A4 (en) * 2004-08-20 2009-08-05 Univ Michigan SMALL MOLECULE INHIBITORS FROM MEMBERS OF THE ANTIOPTOTIC BCL-2 FAMILY AND USES THEREOF
FR2912145B1 (fr) * 2007-02-02 2009-03-06 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008061208A2 (en) * 2006-11-15 2008-05-22 Genentech, Inc. Arylsulfonamide compounds

Also Published As

Publication number Publication date
MX2012003007A (es) 2012-04-11
EA201200472A1 (ru) 2012-10-30
KR20120078715A (ko) 2012-07-10
EA020586B1 (ru) 2014-12-30
WO2011029842A1 (en) 2011-03-17
EP2475661B1 (en) 2013-10-23
AU2010294292A1 (en) 2012-03-01
CN102498111A (zh) 2012-06-13
US8809352B2 (en) 2014-08-19
BR112012005343A2 (pt) 2016-03-22
US20120165298A1 (en) 2012-06-28
EP2475661A1 (en) 2012-07-18
CA2772989A1 (en) 2011-03-17
JP2013504536A (ja) 2013-02-07
ES2443845T3 (es) 2014-02-20

Similar Documents

Publication Publication Date Title
AU2010294292B2 (en) Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer
JP6983273B2 (ja) リジン特異的なデメチラーゼ−1の阻害剤
JP7073359B2 (ja) ユビキチン特異的プロテアーゼ7の阻害剤としてのピペリジン誘導体
AU2017208998B2 (en) Bruton's tyrosine kinase inhibitors
KR102429220B1 (ko) 치환 4-페닐피페리딘, 그 제조 및 사용
ES2944937T3 (es) Tienopirroles en calidad de inhibidores de la histona desmetilasa
TW201823249A (zh) Menin-mll相互作用之稠合二環抑制劑
ES2734268T3 (es) Derivados de urea y amida de aminoalquilpiperazinas y uso de los mismos
KR20200028423A (ko) Rock의 억제제로서의 5-원 및 비시클릭 헤테로시클릭 아미드
TW201350476A (zh) 用於調節表皮生長因子受體(egfr)活性之化合物及組合物
BR112013002182B1 (pt) Compostos derivados de quinolina, composição farmacêutica, inibidor de melk, agente modulador de expressão de melk, agente antitumor, agente terapêutico e/ou preventivo para uma doença que envolve a superexpressão de melk contendo os mesmos e uso dos referidos compostos
KR20230175222A (ko) Nek7 억제제
JP7840334B2 (ja) 芳香族複素環式化合物、薬学的組成物、及びその使用
AU2009318855A1 (en) Lactams as beta secretase inhibitors
KR20240013134A (ko) 시그마 리간드로서 피리딘-술폰아미드 유도체
JP7142010B2 (ja) メニン-mll相互作用のアゼパン阻害剤
WO2020257527A1 (en) Compounds for inhibiting fgfr4
US20100278833A1 (en) Thiophene-imidazopyridines
CN117597346A (zh) Nek7抑制剂
TWI914378B (zh) 作為alk5抑制劑之嗒𠯤基胺基衍生物
TWI912370B (zh) 芳香雜環類化合物、藥物組合物及其應用
WO2019106368A1 (en) Pyrrolo[3,2-c]pyridin-4-one derivatives as pfk inhibitors useful for the treatment of protozoal infections
WO2026039844A1 (en) Stat6 degraders and uses thereof
WO2015016195A1 (ja) Wntシグナル阻害剤
US20090270442A1 (en) Polymorphs of hydrochloride salt of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired